Ablation Technology Industry Growth, Development and Forecast Report, 2030

In 2023, the global ablation technology market generated revenue of USD 5,313.2 million and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030, reaching USD 9,672.9 million by 2030.

This growth can be attributed to the increasing incidence of chronic diseases such as heart disease, cancer, and ophthalmologic, gynecological, and urological conditions. Consequently, there is a heightened demand for effective surgical treatments, driving the need for ablation devices.

Market Trends/Drivers

• Rising awareness about ablation procedures, increased healthcare spending, a growing number of cancer cases, the cost-effectiveness of ablation, and technological advancements in related devices are key factors driving the market.
• The expansion of hospitals and ambulatory surgery centers is expected to further propel market growth.
• The aging population and the rising demand for minimally invasive procedures, due to their advantages over traditional open surgeries, will increase the need for ablation products.

Minimally invasive techniques offer precise results and are cost-effective for both patients and providers. Additionally, these procedures are available for various parts of the body, such as brain surgeries, adrenalectomies, hiatal hernia repairs, colectomies, and nephrectomies, contributing to their widespread popularity.

Download free sample copy of this report: https://www.psmarketresearch.com/market-analysis/ablation-technology-market-report/report-sample

Dominance of Radiofrequency Ablators

• In 2023, the radiofrequency ablation (RFA) segment held the largest market share at 25%.
• It is expected to grow at a CAGR of 9.2% during the forecast period.
• The increased use of RFA for treating conditions like benign and malignant tumors, chronic neck and back pain, and chronic venous insufficiency is driving this segment’s growth.
• RFA is also utilized for treating atrial fibrillation, a condition characterized by irregular heartbeat.
• FDA approvals for advanced RFA devices are anticipated to further boost the market. For example, in December 2022, RF Medical Co. Ltd. received FDA clearance for its MYGEN M-3004 generator and MYOBLATE RFA system for use in the U.S.

Laser ablation also holds a significant market share due to ongoing research. A January 2023 study demonstrated that combining compression therapy with endovenous laser ablation improved the healing rate of venous ulcers and reduced recurrence.

Highest Usage in Cardiovascular Treatments

• In 2023, the cardiovascular segment held the largest market share by application.
• Ablation technology is widely used to treat atrial fibrillation by disrupting the irregular electrical signals responsible for abnormal heartbeats.
• Each cell in the myocardium generates its own signal for heartbeat, and when synchronization fails among cells, arrhythmia (irregular heartbeat) can result.
• Ablation procedures are utilized to block the abnormal electric signals causing arrhythmias, restoring normal heart rhythm.

North America's Market Leadership

In 2023, North America was the largest market for ablation technology, driven by advancements in technology and increased awareness of its applications in various treatments.

The rising number of patients with chronic diseases, particularly cancer, is a major contributor to market growth. Cancer is one of the leading causes of death in the U.S., with the death rate expected to reach approximately 3 million by 2040. Additionally, about 37.3 million people in the U.S. were diagnosed with diabetes, and around 96 million adults were found to have pre-diabetes.

During the forecast period, the Asia-Pacific region is expected to be the fastest-growing ablation technology market, with a CAGR of 9.5%. This growth is driven by increasing awareness of minimally invasive procedures, expanding healthcare systems, and growing economies.

Competitive Landscape

• In October 2022, the Gujarat government allocated INR 22.5 billion for the construction of a multi-specialty hospital at Anusaya Leprosy Hospital, which will offer comprehensive cardiac interventions for various heart conditions.
• In August 2022, Medtronic plc announced the acquisition of Affera Inc. to enhance its cardiac ablation product portfolio by incorporating Affera’s cardiac mapping and navigation technology.

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.